Sei Investments Co. grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 34.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 407,807 shares of the biopharmaceutical company’s stock after purchasing an additional 105,146 shares during the period. Sei Investments Co.’s holdings in Gilead Sciences were worth $28,891,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of GILD. Point72 Asset Management L.P. increased its holdings in shares of Gilead Sciences by 147.9% during the first quarter. Point72 Asset Management L.P. now owns 3,078,566 shares of the biopharmaceutical company’s stock valued at $232,093,000 after purchasing an additional 1,836,662 shares during the period. Farallon Capital Management LLC acquired a new position in shares of Gilead Sciences during the first quarter valued at $137,210,000. State Treasurer State of Michigan increased its holdings in shares of Gilead Sciences by 55.5% during the first quarter. State Treasurer State of Michigan now owns 4,210,424 shares of the biopharmaceutical company’s stock valued at $317,424,000 after purchasing an additional 1,502,700 shares during the period. BlackRock Inc. increased its holdings in shares of Gilead Sciences by 1.4% during the first quarter. BlackRock Inc. now owns 105,236,053 shares of the biopharmaceutical company’s stock valued at $7,933,746,000 after purchasing an additional 1,438,806 shares during the period. Finally, PointState Capital LP acquired a new position in shares of Gilead Sciences during the first quarter valued at $86,570,000. 77.59% of the stock is currently owned by institutional investors.

Gilead Sciences opened at $76.73 on Friday, Marketbeat Ratings reports. The company has a debt-to-equity ratio of 1.23, a current ratio of 3.00 and a quick ratio of 3.23. Gilead Sciences, Inc. has a 1-year low of $64.27 and a 1-year high of $89.54. The firm has a market capitalization of $101.17 billion, a P/E ratio of 11.23, a P/E/G ratio of -5.95 and a beta of 1.03.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.56 by $0.35. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. The business had revenue of $5.65 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same quarter last year, the company posted $2.56 EPS. Gilead Sciences’s revenue for the quarter was down 20.9% on a year-over-year basis. research analysts expect that Gilead Sciences, Inc. will post 6.56 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 27th. Investors of record on Friday, September 14th will be given a $0.57 dividend. The ex-dividend date of this dividend is Thursday, September 13th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.97%. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.

In related news, Director John C. Martin sold 50,000 shares of the stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $77.85, for a total value of $3,892,500.00. Following the completion of the transaction, the director now owns 3,067,762 shares in the company, valued at approximately $238,825,271.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 150,000 shares of company stock valued at $10,839,500 in the last quarter. 1.30% of the stock is currently owned by corporate insiders.

Several research analysts recently weighed in on GILD shares. Morgan Stanley raised their target price on Gilead Sciences from $81.00 to $85.00 and gave the company an “equal weight” rating in a research note on Thursday, July 26th. Barclays decreased their target price on Gilead Sciences from $95.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, May 2nd. Leerink Swann set a $72.00 target price on Gilead Sciences and gave the company a “market perform” rating in a research note on Wednesday, May 2nd. Raymond James started coverage on Gilead Sciences in a research note on Thursday, June 28th. They set a “strong-buy” rating and a $93.00 target price for the company. Finally, BidaskClub raised Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, July 10th. Twelve research analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $88.00.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Story: New Google Finance Tool and Screening Stocks

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.